PT Indofarma (Persero) Tbk, together with its subsidiaries, manufactures and markets pharmaceutical products in Indonesia. More Details
Questionable track record with imperfect balance sheet.
Share Price & News
How has Indofarma (Persero)'s share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: INAF is not significantly more volatile than the rest of ID stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: INAF's weekly volatility has decreased from 13% to 7% over the past year.
7 Day Return
1 Year Return
Return vs Industry: INAF exceeded the ID Pharmaceuticals industry which returned 20.4% over the past year.
Return vs Market: INAF exceeded the ID Market which returned 22.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Indofarma (Persero)'s share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Indofarma (Persero) undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: INAF (IDR2240) is trading above our estimate of fair value (IDR1356.56)
Significantly Below Fair Value: INAF is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: INAF is poor value based on its PE Ratio (290.1x) compared to the ID Pharmaceuticals industry average (25x).
PE vs Market: INAF is poor value based on its PE Ratio (290.1x) compared to the ID market (22.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INAF's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INAF is overvalued based on its PB Ratio (14.3x) compared to the ID Pharmaceuticals industry average (2.4x).
How is Indofarma (Persero) forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Indofarma (Persero) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Indofarma (Persero) performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INAF has high quality earnings.
Growing Profit Margin: INAF's current net profit margins (0%) are lower than last year (0.6%).
Past Earnings Growth Analysis
Earnings Trend: INAF has become profitable over the past 5 years, growing earnings by 9.5% per year.
Accelerating Growth: INAF's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: INAF had negative earnings growth (-99.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9%).
Return on Equity
High ROE: INAF's Return on Equity (0.01%) is considered low.
How is Indofarma (Persero)'s financial position?
Financial Position Analysis
Short Term Liabilities: INAF's short term assets (IDR1,134.7B) exceed its short term liabilities (IDR836.8B).
Long Term Liabilities: INAF's short term assets (IDR1,134.7B) exceed its long term liabilities (IDR446.3B).
Debt to Equity History and Analysis
Debt Level: INAF's debt to equity ratio (105.2%) is considered high.
Reducing Debt: INAF's debt to equity ratio has increased from 51.3% to 105.2% over the past 5 years.
Debt Coverage: INAF's debt is not well covered by operating cash flow (10.3%).
Interest Coverage: INAF's interest payments on its debt are not well covered by EBIT (1.4x coverage).
What is Indofarma (Persero) current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INAF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INAF's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INAF's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INAF's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: INAF is not paying a notable dividend for the ID market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INAF's dividend in 3 years as they are not forecast to pay a notable one for the ID market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Arief Pramuhanto (58 yo)
Mr. Arief Pramuhanto has been President Director of PT Indofarma (Persero) Tbk since May 7, 2019. Mr. Pramuhanto was General Affairs and Human Capital Director at PT Kimia Farma (Persero) Tbk since April 2...
Experienced Management: INAF's management team is considered experienced (3.1 years average tenure).
Experienced Board: INAF's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PT Indofarma (Persero) Tbk's company bio, employee growth, exchange listings and data sources
- Name: PT Indofarma (Persero) Tbk
- Ticker: INAF
- Exchange: IDX
- Founded: 1918
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: Rp6.942t
- Shares outstanding: 3.10b
- Website: https://www.indofarma.id
Number of Employees
- PT Indofarma (Persero) Tbk
- Jalan Indofarma No. 1
- Cikarang Barat
- Jawa Barat
PT Indofarma (Persero) Tbk, together with its subsidiaries, manufactures and markets pharmaceutical products in Indonesia. The company manufactures, trades in, and distributes medicine and medical devices;...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/10 17:09|
|End of Day Share Price||2021/05/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.